0001209191-24-000070.txt : 20240102
0001209191-24-000070.hdr.sgml : 20240102
20240102160643
ACCESSION NUMBER: 0001209191-24-000070
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231220
FILED AS OF DATE: 20240102
DATE AS OF CHANGE: 20240102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Huizenga Theodore Alan
CENTRAL INDEX KEY: 0001603347
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36276
FILM NUMBER: 24502416
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc.
CENTRAL INDEX KEY: 0001515673
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 272546083
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 415-483-8800
MAIL ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-20
0
0001515673
Ultragenyx Pharmaceutical Inc.
RARE
0001603347
Huizenga Theodore Alan
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO
CA
94949
0
1
0
0
SVP, Chief Accounting Officer
0
Common Stock
2023-12-20
4
A
0
1000
0.00
A
24614
D
Common Stock
2024-01-02
4
M
0
3000
21.00
A
27892
D
Stock Option (Right to Buy)
21.00
2024-01-02
4
M
0
3000
0.00
D
2024-01-29
Common Stock
3000
0
D
Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
Includes 278 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023.
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
1/4th of the option vested one year from January 29, 2014 and then 1/48th of the option vested monthly thereafter.
/s/ Karah Parschauer, attorney-in-fact
2024-01-02